标题：肺心病患者血清hs-CRP的改变及阿托伐他汀的干预作用

      作者：蔡志芳，姚汉玲，周胜兰
    （武汉市汉口医院呼吸内科，湖北 武汉 430012）

      卷次： 2013年24卷13期

      【摘要】 目的 探讨慢性肺心病患者血清超敏-C反应蛋白（hs-CRP）的改变及阿托伐他汀的干预作用。
方法 选择 110例慢性肺心病急性加重期患者随机分为A、B两组，选择同期健康体检者50例为对照组（C组），
比较三组血清hs-CRP、肺功能及肺动脉平均压（MPAP）的差别。B组给予基础治疗，A组给予基础治疗同时加用
阿托伐他汀口服，比较两组治疗前后 hs-CRP、肺功能和MPAP的改变。结果 A组、B组两组治疗前血清
hs-CRP、肺功能与MPAP无明显差异，治疗后A、B两组差异有统计学意义。A、B两组患者治疗后 hs-CRP与
MPAP都出现下降，与治疗前相比差异均有统计学意义，A、B两组治疗后对比差异有统计学意义(P<0.05)；FEV1%
与FEV1/FVC治疗前后都上升，差异有统计学意义，A、B两组治疗后对比差异有统计学意义(P<0.01)；A、B两组治
疗后与正常组比较差异仍有统计学意义(P<0.01)。结论 CRP参与慢性肺心病患者的气道炎症反应，阿托伐他
汀可抑制炎症反应并改善肺动脉高压。

      【关键词】 肺心病；C反应蛋白；阿托伐他汀

      【中图分类号】 R541.5 【文献标识码】 A 【文章编号】 1003—6350（2013）13—1900—03


Change of hs-CRP in patients with cor pulmonale and the effect of atorvastatin.
CAI Zhi-fang, YAO Han-ling,
ZHOU Sheng-lan. Respiratory Department, Hankou Hospital of Wuhan, Wuhan 430012, Hubei, CHINA

【Abstract】 Objective To explore the change of hs-CRP in patients with chronic cor pulmonale and the treat-
ment effect of atorvastatin. Methods One hundred and ten patients with acute stage of chronic cor pulmonale were select-
ed and divided into group A and group B randomly. Fifty healthy individuals were selected as the control group (group C).
Comparison was made in respects of hs-CRP, MPAP, lung function in three groups. Group B received basic treatment,
while group A received atorvastatin combined basic treatment. The differences in two groups in respects of hs-CRP, MPAP,
lung function were compared before and after treatment. Results The hs-CRP, lung function and MPAP had no statistical-
ly significant difference between the two groups before treatment, but showed significant difference after treatment. After
treatment, the level of hs-CRP and MPAP decreased in both group A and group B, showing significant difference with
those before treatment. The FEV1% and FEV1/FVC increased after treatment in both group A and group B, which had sig-
nificant difference than that before treatment. But compare to group C, the hs-CRP, MPAP, lung function still had differenc-
es in group A and group B after treatment (P<0.01). Conclusion CRP participates in the pathogenesis of airway inflam-
matory process of cor pulmonale. Atorvastatin can inhibit the inflammatory and improve pulmonale hypertension.

      【Key words】 Cor pulmonale; C-reaction protein; Atorvastatin
·论 著·doi:10.3969/j.issn.1003-6350.2013.13.0788